ClinicalTrials.gg
RecruitingNCT06793215Krascendo 2Updated Nov 5, 2026

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

A Phase 3 interventional study of Divarasib and Pembrolizumab in Non-Small Cell Lung Cancer and KRAS G12C Lung Cancer, sponsored by Hoffmann-La Roche. Recruiting at 299 sites in 28 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.
Updated Nov 5, 2026Site recruiting status changed21 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 182 studies in Carcinoma, Non-Small-Cell Lung by Hoffmann-La Roche — 5 open to participants now, 16 under way, 8 of them phase 3. Carcinoma, Non-Small-Cell Lung · Hoffmann-La Roche.

Planned enrollment
21st of 142
600 · median 136
Started
2025
with 1 other
Phase 3
48 of 182
2 open now
Primary completion
2028-11
later than 10 of 15 live
Registered
178th of 182
by date

Among the 182 studies in Carcinoma, Non-Small-Cell Lung by Hoffmann-La Roche, this one is the 21st largest by planned enrollment of the 142 interventional ones that give a count, is one of 2 that started in 2025, is one of 48 in phase 3, reaches primary completion later than 10 of the 15 other live ones, and was the 178th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

5 of the 182 studies in Carcinoma, Non-Small-Cell Lung by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 182 studies in Carcinoma, Non-Small-Cell Lung by Hoffmann-La Roche, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of divarasib and pembrolizumab compared with pembrolizumab and pemetrexed and carboplatin or cisplatin, for the first-line treatment of adult participants with KRAS G12C-mutated, advanced or metastatic non squamous non-small cell lung cancer (NSCLC).

03

Conditions studied

  • Non-Small Cell Lung Cancer
  • KRAS G12C Lung Cancer

Keywords

  • Advanced Non-Small Cell Lung Cancer
  • KRAS G12 Lung Cancer
  • Advanced Lung Cancer
  • Metastatic lung cancer
  • Divarasib
  • KRAS G12C Inhibitor
  • KRAS G12C Positive
  • KRAS Mutation
  • KRAS G12C Mutation
  • Lung Cancer Mutation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • (ECOG) performance status of 0 or 1
  • or cytologically confirmed diagnosis of advanced or non squamous NSCLC that is not eligible for curative surgery and/or definitive chemoradiotherapy
  • , as defined by v1.1
  • No prior systemic treatment for advanced or metastatic NSCLC
  • Documentation of the presence of a KRAS G12C mutation
  • Documentation of known expression status in tumor tissue
  • Availability of a representative tumor specimen
  • Adequate end-organ function
  • Eligible to receive a platinum-based chemotherapy regimen

Exclusion Criteria Related to NSCLC:

  • Known concomitant second oncogenic driver with available targeted treatment
  • Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases
  • Spinal cord compression not definitively treated with surgery and/or radiation or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for >=2 weeks prior to randomization
  • History of
  • Uncontrolled tumor-related pain
  • Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once a month or more frequently)

Exclusion Criteria Related to Current or Prior Treatments:

  • Any anti-cancer systemic therapy, including hormonal therapy, within 21 days prior to randomization, or is expected to require any other form of antineoplastic therapy while in the study
  • Radiation therapy including palliative RT to bone metastases within 2 weeks prior to randomization and RT to the lung >30Gy within 6 months prior to randomization
  • Prior treatment with KRAS G12C inhibitors or pan-KRAS/RAS inhibitors
  • Treatment with systemic or immunostimulatory medications, including CD137 agonists and immune checkpoint inhibitors
  • Current treatment with medications that are well known to prolong the
  • Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to randomization
  • Prior allogeneic stem cell or solid organ transplantation

Exclusion Criteria Related to General Health:

  • History of other than NSCLC within 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death (e.g., 5-year overall survival [OS] rate >90%), such as adequately treated carcinoma in situ of the cervix, non melanoma skin carcinoma, localized prostate cancer, ductal breast carcinoma in situ, or Stage I uterine cancer
  • Individuals with chronic diarrhea, short bowel syndrome or significant upper gastrointestinal surgery including gastric resection, a history of inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis) or any active bowel inflammation (including diverticulitis), malabsorption syndrome, conditions that would interfere with enteral absorption
  • History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on the screening chest computed tomography scan
  • Significant cardiovascular disease within 3 months prior to screening
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
600 participants (estimated)

Study arms

  • Experimental
    Divarasib + Pembrolizumab

    Participants will receive divarasib orally, once daily (QD) and pembrolizumab via intravenous (IV) infusion every 3 weeks (Q3W)

    Drug: Divarasib · Drug: Pembrolizumab

  • Active comparator
    Pembrolizumab + Pemetrexed + Carboplatin or Cisplatin

    Participants will receive pembrolizumab, pemetrexed and carboplatin or cisplatin via IV infusion Q3W

    Drug: Pembrolizumab · Drug: Pemetrexed · Drug: Carboplatin · Drug: Cisplatin

Interventions

  • Divarasib will be administered orally QD

  • Pembrolizumab will be administered via IV infusion Q3W

  • Pemetrexed will be administered via IV infusion Q3W

  • Carboplatin will be administered via IV infusion Q3W

  • Cisplatin will be administered via IV infusion Q3W

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    PFS is defined as the time from randomization to the first occurrence of disease progression, as determined by blinded independent central review (BICR) according to RECIST v1.1, or death from any cause (whichever occurs first)

    Time frame: Up to approximately 5 years

  2. Overall Survival (OS)

    OS is defined as the time from randomization to death from any cause

    Time frame: Up to approximately 5 years

Secondary outcomes

  1. Objective Response

    Objective response is defined as complete response (CR) or partial response (PR) on two consecutive occasions \>=4 weeks apart, as determined by BICR according to RECIST v1.1

    Time frame: Up to approximately 5 years

  2. Change from Baseline on the European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire-Supplemental Lung Cancer Module (EORTC QLQ-LC13) Cough Scale

    Time frame: Baseline up to Cycle 5 Day 1 (each cycle is 21 days)

  3. Change from Baseline on the EORTC Quality of Life Questionnaire (QLQ-C30) Dyspnea Item and Physical Functioning Scale

    Time frame: Baseline up to Cycle 5 Day 1 (each cycle is 21 days)

  4. Duration of Response (DOR)

    DOR is defined as the time from the first occurrence of a documented objective response to disease progression, as determined by BICR according to RECIST v1.1, or death from any cause (whichever occurs first)

    Time frame: Up to approximately 5 years

  5. Percentage of Participants with Adverse Events (AEs)

    Time frame: Up to approximately 5 years

  6. Number of Participants Reporting Presence, Frequency, Severity, and/or Degree of Interference with Daily Function of Symptomatic Treatment Toxicities Assessed by NCI Patient-Reported Outcomes Common Terminology Criteria for Adverse Events (PRO-CTCAE)

    Time frame: Up to approximately 5 years

  7. Change from Baseline in the Severity of Selected Symptomatic Treatment Toxicities as Assessed Through use of the NCI PRO-CTCAE

    Time frame: Up to approximately 5 years

  8. Frequency of Participants' Response of the Degree they are Troubled with Treatment Symptoms, as Assessed Through use of the single-item EORTC Item List (IL46)

    Time frame: Up to approximately 5 years

  9. Change from Baseline on the EORTC QLQ-C30 and QLQ-LC13 Functional and Global Health Status Score/Quality of Life Score (GHS/QoL)

    Time frame: Up to approximately 5 years

07

Study locations

295 of 299 sites recruiting

Showing the first 100 of 299 sites across 28 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Nov 2028, 37 months after the start.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's planned 37 months is close to that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2025
First posted
Jan 27, 2025
StartActual
Oct 24, 2025
Primary completionEst.
Nov 30, 2028
CompletionEst.
Oct 31, 2030
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
21 sites added, 2 sites removed. 3 sites changed recruiting status (3 now withdrawn)
Show 3 sites
  • Austin Health · Heidelberg, AustraliaRecruiting→Withdrawn
  • Cliniques Universitaires St-Luc · Brussels, BelgiumSuspended→Withdrawn
  • Chungbuk National University Hospital · Cheongju-si, South KoreaRecruiting→Withdrawn
Show 21 added (8 United States, 6 China, 2 Germany, 2 Italy, 1 Denmark, 1 South Africa, 1 United Kingdom)
  • Advent Health Orlando · Orlando, United States
  • Metro-Minnesota Community Oncology Research Consortium · Saint Louis Park, United States
  • AsteraCancer Care · East Brunswick, United States
  • Anhui Provincial Hospital(The First Affiliated Hospital of USTC) · Hefei, China
  • The First Affilicated Hospital, Sun Yat-sen University · Guangzhou, China
  • Yunnan Cancer Hospital · Kunming, China
  • Sjællands Universitetshospital, Køge;Onkologisk Afdeling · Køge, Denmark
  • Christliches Klinikum Halle (Saale) GmbH, Standort Dölau · Halle, Germany
  • Asklepios Klinik Harburg · Hamburg, Germany
  • University of Pretoria Oncology Department · Pretoria, South Africa
  • Grand Valley Oncology · Grand Junction, United States
  • University of Mississippi Medical Center · Jackson, United States
  • WakeMed · Raleigh, United States
  • Gibbs Cancer Center & Research Institute · Greer, United States
  • Spartanburg Medical Center · Spartanburg, United States
  • The First Affiliated Hospital, Zhejiang University School of Medicine - Qingchun Campus - PPDS · Hangzhou, China
  • the First Affiliated Hospital of Bengbu Medical College · Bengbu, China
  • The second Xiangya hospital of central south university · Changsha, China
  • IRCCS Istituto Nazionale Per La Ricerca Sul Cancro (IST) · Genoa, Italy
  • Ospedale di Trento-Presidio Ospedaliero Santa Chiara · Trento, Italy
  • University Hospitals of North Midlands NHS Trust-Royal Stoke University Hospital · Stoke-on-Trent, United Kingdom
Show 2 removed
  • Sjællands Universitetshospital, Roskilde · Roskilde, Denmark
  • Krankenhaus Martha-Maria Halle-Doelau gGmbH · Halle, Germany
across 2 updates, Oct 6, 2026 – Nov 5, 2026
Show all 2 updates
  1. Nov 5, 2026
    11 sites added. Chungbuk National University Hospital is now Withdrawn
    Show 11 added (5 United States, 3 China, 2 Italy, 1 United Kingdom)
    • Grand Valley Oncology · Grand Junction, United States
    • University of Mississippi Medical Center · Jackson, United States
    • WakeMed · Raleigh, United States
    • Gibbs Cancer Center & Research Institute · Greer, United States
    • Spartanburg Medical Center · Spartanburg, United States
    • The First Affiliated Hospital, Zhejiang University School of Medicine - Qingchun Campus - PPDS · Hangzhou, China
    • the First Affiliated Hospital of Bengbu Medical College · Bengbu, China
    • The second Xiangya hospital of central south university · Changsha, China
    • IRCCS Istituto Nazionale Per La Ricerca Sul Cancro (IST) · Genoa, Italy
    • Ospedale di Trento-Presidio Ospedaliero Santa Chiara · Trento, Italy
    • University Hospitals of North Midlands NHS Trust-Royal Stoke University Hospital · Stoke-on-Trent, United Kingdom
    + 1 other change: verification date
  2. Oct 6, 2026
    10 sites added, 2 sites removed. 2 sites changed recruiting status (2 now withdrawn)
    Show 2 sites
    • Austin Health · Heidelberg, AustraliaRecruiting→Withdrawn
    • Cliniques Universitaires St-Luc · Brussels, BelgiumSuspended→Withdrawn
    Show 10 added (3 United States, 3 China, 2 Germany, 1 Denmark, 1 South Africa)
    • Advent Health Orlando · Orlando, United States
    • Metro-Minnesota Community Oncology Research Consortium · Saint Louis Park, United States
    • AsteraCancer Care · East Brunswick, United States
    • Anhui Provincial Hospital(The First Affiliated Hospital of USTC) · Hefei, China
    • The First Affilicated Hospital, Sun Yat-sen University · Guangzhou, China
    • Yunnan Cancer Hospital · Kunming, China
    • Sjællands Universitetshospital, Køge;Onkologisk Afdeling · Køge, Denmark
    • Christliches Klinikum Halle (Saale) GmbH, Standort Dölau · Halle, Germany
    • Asklepios Klinik Harburg · Hamburg, Germany
    • University of Pretoria Oncology Department · Pretoria, South Africa
    Show 2 removed
    • Sjællands Universitetshospital, Roskilde · Roskilde, Denmark
    • Krankenhaus Martha-Maria Halle-Doelau gGmbH · Halle, Germany
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06793215
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jan 27, 2025
Start date
Oct 24, 2025
Primary completion
Nov 30, 2028 (estimated)
Completion
Oct 31, 2030 (estimated)
Last update
Nov 5, 2026

Study contacts

Reference Study ID Number: CO45042 https://forpatients.roche.com/ No attachments to email below.
Contact
global-roche-genentech-trials@gene.com
888-662-6728 (U.S. and Canada)
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Contact
Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Divarasib

Start the discussion